We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Altimmune (ALT) Files IND for Phase I Study on Coronavirus Vaccine
Read MoreHide Full Article
Altimmune, Inc. (ALT - Free Report) announced that it has submitted an investigational new drug (IND) application to the FDA for the clinical development of its COVID-19 vaccine candidate AdCOVID. The IND seeks to initiate a phase I study to evaluate the safety and immunogenicity of single-dose intranasal AdCOVID, which is being developed to stimulate an immune response in the nasal cavity and respiratory tract.
The company plans to begin the clinical study in the fourth quarter of 2020 while data from the same is expected in the first quarter of 2021.
Shares of Altimmune were up 9.1% following the above announcement on Wednesday. In fact, the stock has skyrocketed 433.8% so far this year against the industry’s decrease of 3.8%.
Per the company, AdCOVID is a next-generation vaccine that offers significant benefits compared to other vaccines, which are being studied to fight COVID-19. AdCOVID can be administered as a simple intranasal dose, which can specifically benefit children and can be stored in refrigerators for years. The vaccine is expected to have extended stability at room temperature and can be stored in common refrigerators for more than two years.
Notably, in preclinical studies, AdCOVID demonstrated robust mucosal immunity against the spike protein of the virus.
We note that several drugmakers are working relentlessly to develop a vaccine for the deadly coronavirus disease, which has so far infected 60.4 million people, globally, and killed more than 1.4 million already.
Many drug/biotechs are actively engaged in developing a vaccine to fight the COVID-19 pandemic. Notably, Vaxart (VXRT - Free Report) is evaluating its oral tablet VXA-CoV2-1, a COVID-19 vaccine candidate, in a phase I study. Other companies like CureVac (CVAC - Free Report) and Novavax (NVAX - Free Report) are also seriously pursuing the development of a vaccine against COVID-19.
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.4% per year.
These 7 were selected because of their superior potential for immediate breakout.
Image: Bigstock
Altimmune (ALT) Files IND for Phase I Study on Coronavirus Vaccine
Altimmune, Inc. (ALT - Free Report) announced that it has submitted an investigational new drug (IND) application to the FDA for the clinical development of its COVID-19 vaccine candidate AdCOVID. The IND seeks to initiate a phase I study to evaluate the safety and immunogenicity of single-dose intranasal AdCOVID, which is being developed to stimulate an immune response in the nasal cavity and respiratory tract.
The company plans to begin the clinical study in the fourth quarter of 2020 while data from the same is expected in the first quarter of 2021.
Shares of Altimmune were up 9.1% following the above announcement on Wednesday. In fact, the stock has skyrocketed 433.8% so far this year against the industry’s decrease of 3.8%.
Per the company, AdCOVID is a next-generation vaccine that offers significant benefits compared to other vaccines, which are being studied to fight COVID-19. AdCOVID can be administered as a simple intranasal dose, which can specifically benefit children and can be stored in refrigerators for years. The vaccine is expected to have extended stability at room temperature and can be stored in common refrigerators for more than two years.
Notably, in preclinical studies, AdCOVID demonstrated robust mucosal immunity against the spike protein of the virus.
We note that several drugmakers are working relentlessly to develop a vaccine for the deadly coronavirus disease, which has so far infected 60.4 million people, globally, and killed more than 1.4 million already.
Many drug/biotechs are actively engaged in developing a vaccine to fight the COVID-19 pandemic. Notably, Vaxart (VXRT - Free Report) is evaluating its oral tablet VXA-CoV2-1, a COVID-19 vaccine candidate, in a phase I study. Other companies like CureVac (CVAC - Free Report) and Novavax (NVAX - Free Report) are also seriously pursuing the development of a vaccine against COVID-19.
Zacks Rank
Altimmune currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.4% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>